Literature DB >> 32562858

Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation.

Muhammad Bilal Abid1, Mehdi Hamadani2, Aniko Szabo3, Parameswaran N Hari4, Mary Beth Graham5, Michael O Frank5, William S Collier6, Sameem Abedin4, James H Jerkins4, Marcelo C Pasquini7, Lyndsey Runaas4, Nirav N Shah4, Saurabh Chhabra7.   

Abstract

An increased risk of infections has been described after T cell-replete haploidentical cell transplantation (haploHCT). Cytokine release syndrome (CRS) after haploHCT is a known phenomenon, but the impact of CRS severity on the risk of infections remains unexplored. We retrospectively evaluated 78 consecutive adult haploHCT recipients from 2012 to 2018 for the development of CRS (graded based on the criteria of Lee et al) and examined the incidence and mortality due to infections in correlation with CRS severity. In our study cohort, which was stratified into 3 groups by severity of CRS, 80% of the patients developed infections within 180 days of HCT. Significantly higher proportions of patients with CRS grade 2 (89%) and grade ≥3 (90%) than patients with CRS grade 0-1 (68%) had at least 1 infection in the first 100 days (P = .04). Bloodstream infections (BSIs) were seen more frequently in patients with CRS grade 2 and grade ≥3 in the first 6 months. Multivariable analysis for time to infection showed that CRS grade ≥3 was independently associated with an elevated risk of any infection compared with CRS grade 0-1 (hazard ratio [HR], 3.05; P = .007). CRS grade ≥3 was also associated with a higher hazard of viral (HR, 3.42; P = .04) and bacterial infections (HR, 2.83; P = .03) compared with CRS grade 0-1. After adjusting for time to neutrophil engraftment as a time-dependent covariate, CRS grade ≥3 still had a significant effect on viral infections (HR, 2.49; P = .03), but not on bacterial infections (HR, 1.32; P = .57). CRS grade was also a significant predictor for infection density (overall, bacterial, and viral). The incidence of infection-related mortality by day +100 was higher in patients with severe CRS. Severe CRS developing after post-transplantation cyclophosphamide-based haploHCT is independently associated with viral infections and an increased risk of bacterial infections, likely through delayed neutrophil engraftment.
Copyright © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bacterial infections; Cytokine release syndrome; Haploidentical related donor hematopoietic cell transplantation; Infections; Post-transplantation cyclophosphamide

Mesh:

Substances:

Year:  2020        PMID: 32562858     DOI: 10.1016/j.bbmt.2020.06.006

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  3 in total

1.  Early administration of cyclosporine may reduce the incidence of cytokine release syndrome after HLA-haploidentical hematopoietic stem-cell transplantation with post-transplant cyclophosphamide.

Authors:  Naoki Kurita; Tatsuhiro Sakamoto; Takayasu Kato; Manabu Kusakabe; Yasuhisa Yokoyama; Hidekazu Nishikii; Mamiko Sakata-Yanagimoto; Naoshi Obara; Yuichi Hasegawa; Shigeru Chiba
Journal:  Ann Hematol       Date:  2021-02-12       Impact factor: 3.673

2.  Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation.

Authors:  Rémy Duléry; Razan Mohty; Myriam Labopin; Simona Sestili; Florent Malard; Eolia Brissot; Giorgia Battipaglia; Clémence Médiavilla; Anne Banet; Zoé Van de Wyngaert; Annalisa Paviglianiti; Ramdane Belhocine; Françoise Isnard; Simona Lapusan; Rosa Adaeva; Anne Vekhoff; Tounes Ledraa; Ollivier Legrand; Ariel Cohen; Agnès Bonnin; Stéphane Ederhy; Mohamad Mohty
Journal:  JACC CardioOncol       Date:  2021-06-15

3.  Haploidentical Hematopoietic Stem Cell Transplantation in Leukemia's: Experience from a Cancer Center in India.

Authors:  Ankit Batra; Jayachandran Perumal Kalaiyarasi; Krishnarathinam Kannan; Nikita Mehra; Prasanth Ganesan; Parathan Karunakaran; Manikandan Dhanushkodi; Gangothri Selvarajan; Arun Kumar Rajan; Sivasree Kesana; Trivadi Ganesan; Tenali G Sagar; Venkatraman Radhakrishnan
Journal:  Indian J Hematol Blood Transfus       Date:  2020-10-27       Impact factor: 0.915

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.